Clinorion

Crohn’s disease biologic and immunomodulator therapies

Crohn’s disease therapy is best organized by mechanism of action, because that helps clinicians compare efficacy, speed of onset, route, dosing interval, safety, and fit for specific disease phenotypes. In current practice, therapy choice should also reflect whether disease is predominantly inflammatory, fistulizing/penetrating, or fibrostenotic/stricturing, because biologics work better for some phenotypes than others (AGA 2025, ECCO 2024).

Learning objectives

Classify Crohn’s disease therapies by mechanism of action.
Compare dosing, treatment course, interval, and safety for each medication.
Interpret pivotal clinical trial evidence using PICO.
Match therapy choice to major Crohn’s phenotypes, including luminal inflammatory, fistulizing, penetrating, and stricturing disease.
Apply current guideline recommendations to biologic-naïve and biologic-exposed patients.

Phenotype-based treatment framing

Why phenotype matters

Predominantly inflammatory luminal disease: multiple advanced therapies are effective; anti-TNF, ustekinumab, IL-23 inhibitors, vedolizumab, and upadacitinib are all reasonable depending on prior exposure and patient factors (AGA 2025, ECCO 2024).
Fistulizing / penetrating disease: anti-TNF therapy, especially infliximab, has the strongest evidence base and is generally the most established first biologic choice, particularly for perianal fistulas (ECCO 2024, AGA 2025).
Stricturing / fibrostenotic disease: medical therapy may help if there is an active inflammatory component, but established fibrotic strictures often need endoscopic dilation or surgery; no biologic has strong evidence that it reverses fixed fibrosis (ECCO 2024).
Postoperative recurrence prevention: anti-TNF agents and other biologics can be used in higher-risk patients, but this lesson focuses on active luminal/penetrating disease treatment rather than postoperative algorithms (ECCO 2024).

Treatment framework by mechanism

Major classes

Anti-TNF inhibitors: infliximab, adalimumab, certolizumab pegol
Anti-integrin therapy: vedolizumab; natalizumab is a legacy option with major safety limitations
IL-12/23 blockade: ustekinumab
Selective IL-23 (p19) blockade: risankizumab, mirikizumab, guselkumab
JAK pathway / small molecule: upadacitinib
Conventional immunomodulators: azathioprine, 6-mercaptopurine, methotrexate

Anti-TNF inhibitors

Mechanism: These agents neutralize TNF-α, a major cytokine driving intestinal inflammation, leukocyte recruitment, granulomatous inflammation, and tissue injury (ECCO 2024, Remicade PI, Humira PI, Cimzia PI).
Phenotype fit: Best-established class for fistulizing/perianal Crohn’s disease and still one of the most important options for severe inflammatory luminal disease (ECCO 2024, AGA 2025).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Guideline / phenotype overview
Infliximab / Remicade (plus biosimilars)	5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks; dose intensification is common for secondary loss of response (Remicade PI).	Serious infection, TB/HBV reactivation, infusion reactions, delayed hypersensitivity, psoriasis/paradoxical rash, worsening heart failure, demyelination, rare lymphoma and NMSC. Watch for fever, dyspnea, chest tightness, rash, neuropathy, edema (Remicade PI).	Recommended in AGA 2025. Best-established biologic for perianal fistulizing disease and a strong option for severe inflammatory luminal disease. In thiopurine-naïve patients starting infliximab, AGA suggests combination with a thiopurine over monotherapy (AGA summary).
Adalimumab / Humira (plus biosimilars)	160 mg SC on day 1, 80 mg on day 15, then 40 mg every other week beginning day 29; some patients escalate to weekly dosing (Humira PI).	Serious infection, TB/HBV reactivation, injection-site reactions, paradoxical psoriasis, demyelination, heart failure signal, rare lymphoma/NMSC. Watch for fever, cough, shingles, neuropathy, chest pain (Humira PI).	Recommended by AGA 2025. Good option for inflammatory luminal disease and used in fistulizing disease, although infliximab has the strongest classic fistula-specific evidence.
Certolizumab pegol / Cimzia	400 mg SC at weeks 0, 2, and 4, then 400 mg every 4 weeks for responders (Cimzia PI).	Serious infection, TB/HBV reactivation, injection reactions, rash, demyelination, heart failure signal. Watch for infection, neurologic symptoms, dyspnea, edema (Cimzia PI).	Suggested, but less strongly positioned than higher-efficacy options in AGA 2025. Can still be considered for inflammatory luminal disease in selected cases.

Anti-integrin therapy

Mechanism: These drugs block leukocyte trafficking into the gut. Vedolizumab selectively targets α4β7 integrin, giving it gut-selective activity; natalizumab blocks broader α4 integrin signaling and is rarely used because of PML risk (Entyvio PI, Tysabri PI).
Phenotype fit: Best for inflammatory luminal disease when a gut-selective safety profile is attractive; not the top phenotype-specific choice for fistulizing disease (AGA 2025, ECCO 2024).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Trials (PICO + detailed results)	Guideline / phenotype overview
Vedolizumab / Entyvio	300 mg IV at weeks 0, 2, and 6, then every 8 weeks; SC maintenance is 108 mg every 2 weeks after IV induction in appropriate patients (Entyvio PI).	Headache, arthralgia, nasopharyngitis, infusion or injection reactions; infection risk remains relevant. Watch for fever, cough, hypersensitivity symptoms (Entyvio PI).		Suggested by AGA 2025. Particularly useful for inflammatory luminal disease when a more gut-selective mechanism is desired. Less compelling for fistulizing phenotype than anti-TNF therapy.
Natalizumab / Tysabri	300 mg IV every 4 weeks; usually stopped if no benefit by 12 weeks; avoid with other potent immunosuppression (Tysabri PI).	PML risk is the dominant limitation, plus infection and infusion reactions. Watch for focal neurologic deficits, cognitive change, visual symptoms, progressive weakness (Tysabri PI).		Rarely used in current practice because of safety concerns despite historical efficacy data (ECCO 2024).

IL-12/23 blockade

Mechanism: Ustekinumab binds the shared p40 subunit of IL-12 and IL-23, reducing downstream Th1/Th17 signaling (Stelara PI, UNITI / IM-UNITI).
Phenotype fit: Strong option for inflammatory luminal disease; less phenotype-specific evidence for fistulas than anti-TNF therapy, but commonly used after anti-TNF exposure or when a non-TNF biologic is preferred (AGA 2025).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Trials (PICO + detailed results)	Guideline / phenotype overview
Ustekinumab / Stelara	Single weight-based IV induction (260 mg if ≤55 kg; 390 mg if >55 to 85 kg; 520 mg if >85 kg), then 90 mg SC at week 8 and every 8 weeks thereafter (Stelara PI).	URTI, headache, arthralgia, infection risk, rare hypersensitivity, rare posterior reversible encephalopathy signal. Watch for infection, severe headache, vision change, allergic reaction (Stelara PI).		Recommended by AGA 2025. Strong non-TNF option for inflammatory luminal disease. For fistulizing disease, anti-TNF still has more phenotype-specific evidence.

Selective IL-23 (p19) inhibitors

Mechanism: These agents selectively block the p19 subunit of IL-23, an increasingly important target in Crohn’s disease treatment (AGA 2025, Skyrizi PI, Omvoh PI, Tremfya PI).
Phenotype fit: Excellent options for inflammatory luminal Crohn’s disease, especially after anti-TNF exposure or when a potent non-TNF biologic is preferred. Fistula-specific evidence remains less developed than for anti-TNF therapy (AGA 2025, ECCO 2024).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Guideline / phenotype overview
Risankizumab / Skyrizi	600 mg IV at weeks 0, 4, and 8, then 180 mg or 360 mg SC starting at week 12 and every 8 weeks thereafter (Skyrizi PI).	URTI, headache, arthralgia, abdominal pain, injection-site reactions, infection risk. Watch for fever, cough, worsening abdominal pain, allergic reaction (Skyrizi PI).	Recommended by AGA 2025 and considered one of the stronger non-TNF options for inflammatory luminal disease, including biologic-exposed patients.
Mirikizumab / Omvoh	900 mg IV at weeks 0, 4, and 8, then 300 mg SC every 4 weeks starting at week 12 (Omvoh PI).	Infections, injection reactions, hepatotoxicity signal, TB risk screening required. Watch for jaundice, dark urine, fever, cough, hypersensitivity (Omvoh PI).	Recommended in AGA 2025. Strong option for inflammatory luminal disease, especially when selecting a potent non-TNF biologic.
Guselkumab / Tremfya	Induction: either 200 mg IV at weeks 0, 4, and 8 or 400 mg SC at weeks 0, 4, and 8. Maintenance: 100 mg SC every 8 weeks starting week 16 or 200 mg SC every 4 weeks starting week 12 (Tremfya PI).	Infections, injection reactions, hypersensitivity, liver-test abnormalities. Watch for fever, cough, jaundice, pruritus, swelling (Tremfya PI).	Recommended by AGA 2025. Strong choice for inflammatory luminal disease and increasingly important in post-biologic sequencing.

JAK pathway / small-molecule therapy

Mechanism: Upadacitinib is an oral JAK inhibitor that interrupts intracellular cytokine signaling rather than a single extracellular cytokine target (Rinvoq PI, NEJM Upadacitinib 2023).
Phenotype fit: Best thought of as a rapid-onset inflammatory luminal disease option, especially after biologic exposure. It does not have the same phenotype-specific fistula evidence base as infliximab (AGA 2025).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Trials (PICO + detailed results)	Guideline / phenotype overview
Upadacitinib / Rinvoq	45 mg PO daily for 12 weeks for induction, then 15 mg PO daily for maintenance; 30 mg daily may be used in selected refractory or extensive disease, using the lowest effective dose (Rinvoq PI).	Serious infection, herpes zoster, malignancy, MACE, thrombosis, hepatic abnormalities, neutropenia, rare GI perforation. Watch for shingles, fever, chest pain, dyspnea, unilateral leg swelling, severe abdominal pain (Rinvoq PI).		Recommended by AGA 2025. Most useful when an oral option and rapid onset are priorities, particularly in inflammatory luminal disease after prior biologic exposure.

Conventional immunomodulators

Mechanism:

Thiopurines impair purine synthesis and lymphocyte proliferation.
Methotrexate inhibits folate-dependent pathways and suppresses immune activation (AGA 2025, ECCO 2024).

Phenotype fit: These are not the leading agents for fistulizing or severe penetrating disease in modern practice. Their main role is selective maintenance, steroid-sparing, or combination therapy rather than rapid induction of severe inflammatory disease (AGA 2025).

Medication (generic / brand)	Typical dosing / interval	Notable adverse effects / symptoms to watch for	Guideline / phenotype overview
Azathioprine / Imuran	Usually 2 to 2.5 mg/kg/day PO; slow onset, often 8 to 12+ weeks. Obtain TPMT and/or NUDT15 testing before treatment (AGA 2025, ECCO 2024).	Leukopenia, infection, hepatotoxicity, acute pancreatitis, nausea, lymphoma/NMSC risk. Watch for fever, sore throat, bruising, jaundice, severe epigastric pain (ECCO 2024).	AGA 2025 suggests against thiopurine monotherapy for induction but supports thiopurines as a maintenance option in selected patients.
6-Mercaptopurine / Purinethol	Usually 1 to 1.5 mg/kg/day PO; slow onset similar to azathioprine; TPMT/NUDT15 testing recommended before use (AGA 2025, ECCO 2024).	Myelosuppression, hepatotoxicity, infection, pancreatitis, lymphoma/NMSC risk. Watch for fever, jaundice, bruising, abdominal pain (ECCO 2024).	Same overall positioning as thiopurines: selective maintenance/steroid-sparing role, not a preferred induction therapy for severe inflammatory or fistulizing disease (AGA 2025).
Methotrexate / Trexall, Otrexup, Rasuvo	Preferred Crohn regimen is 25 mg SC/IM weekly for induction, then 15 mg weekly for maintenance; give folic acid. Oral methotrexate is not preferred for Crohn’s induction/maintenance (AGA 2025, NEJM 1995, NEJM 2000).	Nausea, fatigue, hepatotoxicity, cytopenias, stomatitis, infection, rare pneumonitis; teratogenic. Watch for dyspnea, cough, oral ulcers, bruising, severe nausea, jaundice (ECCO 2024).	AGA 2025 suggests parenteral methotrexate over no treatment and suggests against oral methotrexate monotherapy. Best used for inflammatory luminal disease when a steroid-sparing non-biologic option is needed.

Practical phenotype-based comparison

Phenotype / scenario	Most favored therapies	Comments
Moderate-to-severe inflammatory luminal disease	Anti-TNF, ustekinumab, risankizumab, guselkumab, mirikizumab, vedolizumab, upadacitinib	Choice depends on prior biologic exposure, need for rapid onset, comorbidity profile, and patient preference (AGA 2025).
Perianal fistulizing disease	Infliximab first; other anti-TNFs also used	Most evidence-supported phenotype-specific biologic strategy; combine with drainage/seton/surgery when needed (Present 1999, ECCO 2024).
Penetrating disease	Anti-TNF often preferred	Especially when abscess/fistula burden suggests aggressive inflammatory disease; source control remains essential (ECCO 2024).
Stricturing disease with inflammatory component	Biologic therapy can help the inflammatory component	Biologics do not reliably reverse fixed fibrosis; think early about imaging, dilation, or surgery if obstructive symptoms persist (ECCO 2024).
Need for gut-selective mechanism	Vedolizumab	Useful when infection/systemic safety profile is a major consideration (Entyvio PI).
Need for oral rapid-onset therapy	Upadacitinib	Strong efficacy, but safety counseling is more intensive (NEJM Upadacitinib 2023, Rinvoq PI).
Need for potent non-TNF biologic	Risankizumab, guselkumab, mirikizumab, ustekinumab	Especially attractive after anti-TNF exposure or when avoiding TNF blockade is preferred (AGA 2025).

Key clinical pearls

Anti-TNF remains the most phenotype-specific class for fistulizing Crohn’s disease, especially infliximab (Present 1999, ECCO 2024).
Stricturing disease requires careful distinction between inflammatory narrowing and fixed fibrosis; biologics help the former more than the latter (ECCO 2024).
IL-23 agents are increasingly important for inflammatory luminal Crohn’s disease, especially after prior biologic failure (AGA 2025).
Vedolizumab is useful when gut-selective therapy is desirable, but it is not usually the go-to phenotype-specific choice for complex fistulas.
Upadacitinib is one of the fastest oral options, but requires more extensive safety counseling than most biologics.

Crohn’s Disease Antibody and Small Molecule Therapy